Trial CTSU-EA1211


Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial

Type: Diagnostic
Phase: Phase II
Status: Open to Accrual
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Peter Conti, MD,PHD
Other Trial Staff:  Melissa Perkins, Coordinator, Mario Franco, Coordinator, Kimberly Arieli, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.